ScripPublicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the
ScripITM Isotope Technologies Munich is preparing the complex logistics and manufacturing it will need for commercial launch of ITM-11 (non-carrier-added 177 Lu-edotreotide), its radiopharmaceutical candid
ScripThe market for targeted radiotherapy in oncology could soon become a bit more competitive as ITM Isotope Technologies Munich unveiled topline Phase III results for ITM-11 (non-carrier-added 177 Lu-edo
ScripThe radiopharmaceutical space saw a couple of huge deals at the end of last year, and another flurry, albeit on a rather smaller scale, happened this week. On September 12, both Sanofi and ITM Isot